The first vaccine against monkeypox has passed preliminary qualification

 • 14049 переглядiв

The MVA-BN vaccine has been prequalified by the WHO for the control of monkeypox. It is 82% effective with two doses and is recommended for people over 18 years of age at high risk of infection.

The first vaccine against monkeypox - MVA-BN - has passed preliminary qualification by the WHO, the World Health Organization (WHO) said in a statement, UNN reports .

Details

The approval of the prequalification is expected to facilitate timely and expanded access to the vaccine in communities with acute need, reduce transmission and help contain the outbreak.

WHO's assessment for prequalification is based on information provided by the manufacturer, Bavarian Nordic A/S, and a review by the European Medicines Agency, the regulatory authority that registers the vaccine.

Is there a global pandemic: infectious disease specialist Olga Golubovskaya talks about forecasts for it9/13/24, 12:36 PM

This first pre-qualification of a smallpox vaccine is an important step in our fight against the disease, both in the context of current outbreaks in Africa and in the future

- WHO Director-General Tedros Adanom Ghebreyesus said. 

MVA-BN vaccine can be administered to people over 18 years of age as a 2-dose injection at 4-week intervals. After preliminary cold storage, the vaccine can be stored at 2-8 °C for up to 8 weeks.

WHO: $135 million needed to tackle monkeypox outbreak24.08.24, 06:54

The WHO Strategic Advisory Group of Experts (SAGE) on Immunization reviewed all available evidence and recommended that MVA-BN be used in the context of a smallpox outbreak for persons at high risk of infection. Although MVA-BN is not currently licensed for persons under 18 years of age, it may be off-label in infants, children and adolescents, as well as in pregnant and immunocompromised individuals. This means that the use of the vaccine is recommended in an outbreak situation where the benefits of vaccination outweigh the potential risks.

According to research, a single dose of MVA-BN vaccine administered before infection is 76% effective in protecting people from monkeypox. In the case of two doses of the vaccine, the figure increases to 82%. 

Addendum

More than 120 countries have confirmed more than 103,000 cases of monkeypox since the global outbreak began in 2022. In 2024 alone, there were 25,237 suspected and confirmed cases and 723 deaths from various outbreaks in 14 countries in the African region (based on data as of September 8, 2024).

Another 1,200 cases of monkeypox detected in Africa over the week18.08.24, 20:37

Tatiana Kraevskaya Health
Popular
Zelenskyy revealed details of Iran's lies about supplying thousands of drones to Russia

 • 11727 переглядiв

Resident Evil Requiem game sets historic sales record for the series

 • 14385 переглядiв

IMF concerned about Ukraine's financing due to parliamentary delays

 • 19074 переглядiв

Iranian FPV drones attacked a US airbase in Iraq while Trump rejects aid to Ukraine

 • 6424 переглядiв

News by theme
The first vaccine against monkeypox has passed preliminary qualification

 • 14049 переглядiв

Bitcoin fell to $57 thousand amid rumors of a rate cut

 • 17009 переглядiв

Investigation of large-scale tax evasion scheme at Chernivtsi customs completed

 • 11854 переглядiв

Adaptation of displaced children in Kyiv region - it is important for them to study offline

 • 49924 переглядiв

Ukraine has become the country with the highest mortality rate in the world - CIA report

 • 12616 переглядiв

Russian air strike on Yampol: two dead, no electricity supply

 • 13816 переглядiв